Radium-223 should not be routinely added to cabozantinib for RCC with bone metastases based on the phase II RADICAL trial. The study found no skeletal-event benefit, no improvement in progression-free survival or response rate, and it crossed a prespecified futility boundary.

Why It Matters To Your Practice

• Bone metastases in RCC drive pain, fracture risk, spinal complications, and urgent care needs, so clinicians need supportive strategies that add value without undermining systemic therapy.

• RADICAL is important because it tested a bone-directed combination in this setting and did not show a clinical benefit to justify routine use of radium-223 with cabozantinib outside a trial setting. Radium-223 is not approved for RCC.

Clinical Implications

• In RADICAL, median symptomatic skeletal event-free survival was 16.7 months with radium-223 plus cabozantinib versus 17.6 months with cabozantinib alone. Median overall survival was numerically longer with the combination, but the study was too small and follow-up too limited to establish a survival benefit.

• The combination's overall safety was described as manageable, with no apparent fracture signal in the selected study population. Still, blood-count abnormalities, especially lymphopenia, were more frequent with the combination arm. Trial design matters: osteoclast-targeted therapy was required unless contraindicated, and patients with imminent fracture or cord compression were excluded. The lower median daily cabozantinib dose in the combination arm partly reflected a lower protocol-specified starting dose, not a demonstrated interaction forcing dose reduction across practice settings.

Insights

• If bone-modifying therapy is needed, denosumab and zoledronic acid remain the principal osteoclast-targeted options discussed for RCC bone metastases, but neither replaces systemic RCC treatment or local management of unstable or symptomatic lesions.

• An RCC-specific efficacy advantage of denosumab over zoledronic acid has not been established. In broader solid-tumor data, denosumab was noninferior to zoledronic acid for delaying first skeletal-related events, but that should not be treated as proof of superiority in RCC. Zoledronic acid has older RCC-specific placebo-controlled subgroup data suggesting reduced skeletal morbidity, but those data predate contemporary RCC therapy and do not establish superiority over denosumab.

The Bottom Line

• For clinicians, the practical takeaway is to avoid routine radium-223 plus cabozantinib in RCC bone metastases outside a clinical trial.

• Supportive care should instead center on appropriate systemic therapy, consideration of denosumab or zoledronic acid when suitable, and prompt radiotherapy, stabilization, or urgent assessment for painful, structurally dangerous, or potentially compressive lesions. Choice between denosumab and zoledronic acid is driven more by renal function, hypocalcemia risk, dental risk, and logistics than by proven RCC-specific efficacy differences.

Please review content for accuracy. You are the final authority.